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1. INTRODUCTION 
 
1.1 ORALLY DISINTEGRATING TABLETS 1, 2 
Among the different routes of administration, the oral route of administration 
continues to be the most preferred route due to various advantages including ease of 
ingestion, avoidance of pain, versatility and most importantly patient compliance. The 
important drawback of tablets and capsules dosage forms for pediatric and geriatric 
patients is they are facing difficulty in swallowing. 
 
Nearly 35% of the general population, especially the elderly patients and children suffer from 
dysphasia or difficulty in swallowing, which results in high incidence of noncompliance and 
ineffective therapy. Swallowing problems also are very common in young individuals 
because of their poorly developed muscular and nervous systems. Other groups who may 
experience problems in swallowing conventional oral dosage forms are the patients with 
tremors of extremities, mentally ill, developmentally disabled, non co-operative patients and 
patients with reduced liquid intake plans or patients suffering from nausea. The swallowing 
problems are also common in some cases such as patients with motion sickness, sudden 
episodes of allergic attack or coughing and due to lack of water. 
 
Recent advances in technology have presented viable dosage alternative for patients who may 
have difficulty in swallowing tablets or capsules. Traditional tablets and capsules 
administered with an 8-oz. glass of water may be inconvenient or impractical for some 
patients. 
 
To overcome these problems, formulators have considerably dedicated their effort to 
develop novel drug delivery systems (NDDS) which enhance safety and efficacy of 
drug molecule and to achieve better patient compliance. One such approach is ‘Oral 
dispersible Tablets’, which disintegrate or dissolve in saliva and are swallowed 
without water as tablet disintegrate in mouth, this could enhance the clinical effect of 
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drug through pregastric absorption from the mouth, pharynx, esophagus. This leads to 
an increase in the bioavailability by avoiding first pass liver metabolism. 
The centre for drug evaluation and research states an orally dissolving tablet to be “A dosage 
form containing medicinal substances, which disintegrates rapidly, usually within a matter of 
seconds, when placed upon tongue.” This system is recognized with other synonyms like fast 
dissolving tablets; melt in mouth tablets, porous tablets, rapidly disintegrating tablets, quick 
dissolving, and rapimelt tablets. Despite various nomenclatures the function and concept of 
all these Drug Delivery System (DDS) is similar. 
 
                                        Figure 1 : Consumer Acceptance for ODT3 
Above figure 1, shows that nearly 70% of the patient’s population would ask for ODT and 
would purchase ODT. Whereas, nearly 90% of the patient’s population would prefer only 
ODT compare to regular tablets or liquids.3 
The advantages of orally disintegrating tablets are being recognized in both industry and 
academia. Their growing importance was underlined recently when the European 
Pharmacopoeia adopted the term Oro-dispersible tablet as a “tablet to be placed in the 
mouth where it disperses rapidly before swallowing”. 
 
                                                                                                     Introduction                          
         
                                                                                                                                         Page 14                           
Figure 2 : Disintegration of tablet  in mouth4 
Above figure 2, shows that as soon as ODT kept in the mouth it disintegrate  rapidly within a 
matter of seconds and disperse thoroughly in oral cavity.4 
 
Advantages of Oro-dispersible formulation4 
 Improved patient compliance is the primary benefit of this technology. 
 Administration to patients who cannot swallow and patients who refuse to swallow such 
as pediatric, geriatric and psychiatric patients. 
 Can be produced at industrial scale more simply and more efficiently. 
 No need of water for swallowing the dosage forms. This is highly convenient feature for 
the patients who are traveling or do not have immediate access to water. 
 Superior taste of the tablet that helps to change the basic view of medications as the 
“bitter pill” particularly for pediatric patients. 
 More rapid drug absorption through pre-gastric absorption from the mouth, pharynx and 
oesophagus. 
 The fast dissolving dosage forms combines the benefit of liquid formulation with those of 
solid oral dosage forms. 
 A wide range of drugs can be considered as a candidate for this dosage forms, (e.g. anti 
pyretic, analgesics, anti inflammatory agents, coronary vasodilators, antibiotics, anti-
asthmatic agents, diuretics, anti arrhythmic, anti epileptics, antihistamines, anti- emetics 
and anti hypertensives). 
 Added benefits of convenience and accurate dosing as compared to liquids. 
 
Disadvantages of Oro-dispersible formulation 4 
 Drugs absorbed at specific site cannot be given in these dosage forms. 
 These tablets show high friability, less hardness than conventional tablets. 
 
1.2 CHALLENGES TO DEVELOP ORO-DISPERSIBLE TABLET 5 
1) Taste of the medicament: 
As most of drugs are unpalatable, Orodispersible drug delivery system usually contain the 
medicament in a taste masked form. Delivery systems dissolve or disintegrate in the patient’s 
mouth, thus releasing the active ingredients which come in contact with the taste buds and 
hence, taste masking of drug becomes critical for patient compliance. 
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2) Hygroscopicity: 
Several Orodispersible dosage forms are hygroscopic and can’t maintain physical integrity 
under normal conditions of temperature and humidity. Hence, they need protection from 
humidity which calls for specialized product packaging. 
3) Friability: 
In order to allow Orodispersible tablets to dissolve or disintegrate in oral cavity, they are 
made of either porous or compressed into tablets with very low compression force, which 
makes the tablets friable which are difficult to handle, often requiring specialized peel-off 
blister packing. 
 
Biopharmaceutical consideration:6-7 
Elderly   do  not  respond  to  the  drug  therapy  in  the  same  manner  as  young  adult. 
Several  age  related  changes  in the  gastrointestinal tract  have the  potential effect to  alter 
the drug absorption, which  effect overall  drug  absorption  hence  the drug efficacy.  
 
Pharmacokinetics:  The  altered  drug  binding to  serum   albumin  has been  extensively  
studied in  geriatric  patients.  A  decrease  in lean body  and  total body water  is expected to 
result in  decrease  volume of  distribution  (Vd),  of  lipid soluble  drugs.  The  decrease in 
liver volume  and regional  blood flow  to  the  liver  reduces  the  biotransformation  of  drugs  
through  oxidation,  reduction  and  hydrolysis.  The  drug  excreted by renal  clearance  is  
slowed,  thus  half-life  of  renal  excreted  drugs increased. 
 
Pharmacodynamics:   Drug receptor interaction  are  impaired  in  elderly  as  well as  in  
young ones  due  to the  under  development  of organs.8  
 Decreased ability of the body to  respond  baroreflexive stimuli,  cardiac  output,  and  
orthostatic  hypotension  may  seen in  taking  antihypertensive  like  prazocin. 
 Decreased sensitivity of the  CVS to β-adrenergic  agonist  and antagonist. 
 Immunity is less  and taken  into consideration while administered antibiotics. 
 Altered  response  to  drug therapy- elderly  show  diminished  bronchodilator effect  
of  theophylline  shows  increased  sensitivity  to  barbiturates. 
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 Concomitant illnesses  are often  present in  elderly,  which  is  also  taken  into  
consideration, while multi-drug therapy  is prescribed. 
 The incidence  of  diabetes  and  glucose  tolerance is well  documented  and  hence  
every  attempt is  made to  avoid  sugar-containing  excipients. 
    Increasing the number  of  medication  results  in more  complex  dosing  interval, dosage  
regimen and  difficulties  in  dosage from  design. 
 
Conventional Techniques4,5,9 
1) Tablet molding:  
In this method, the delivery system is prepared in the form of tablets using water-
soluble additives; allow the tablets to dissolve rapidly and completely in mouth. All 
the ingredients of the formulation are passed through fine mesh, dry blended, wetted 
with a hydro-alcoholic solvent and then compressed into tablets using low 
compression forces.  
2) Freeze drying (Lyophilization):  
Lyophilization is a pharmaceutical manufacturing technology, which allows drying of 
heat sensitive drugs and biological at low temperatures under conditions that allow 
removal of water by sublimation. Lyophilization results in preparations of highly 
porous, with a very high specific surface area, which dissolve rapidly and show 
improved absorption and bioavailability.  
3) Spray drying: 
Spray drying is a process by which highly porous fine powders can be produced. The 
composition contains a bulking agent (e.g. mannitol and lactose), disintegrant (e.g. 
sodium starch glycollate and croscarmellose sodium), an acidic ingredient (citric acid) 
and/or alkaline ingredients (e.g. sodium bicarbonate) which when compressed into 
tablets shows fast disintegration and enhanced dissolution.  
4)  Sublimation: 
Because of low porosity, compressed tablets composed of highly water-soluble 
excipients as tablet matrix material often do not dissolve rapidly in water.  Porous 
tablets that exhibit good mechanical strength and dissolve quickly have been 
developed.  Inert solid ingredients (e.g., urea, urethane, ammonium carbonate, 
camphor, naphthalene) were added to other tablet excipients and the blend was 
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compressed into tablet.  Removal of volatile material by sublimation generated a 
porous structure. Compressed tablets containing mannitol and camphor have been 
prepared by sublimation technique.  The tablets dissolve within 10-20 seconds and 
exhibit sufficient mechanical strength for particle use.  
      
Figure 3 :  Steps involved in development of the mouth dissolving tablets by 
sublimation technique 
                     
Figure 4 : Schematic Diagram of Sublimation Technique for preparation of 
MDT 
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5)  Addition of Disintegrant:  
Addition of disintegrant in fast dissolving tablets, leads to quick disintegration of 
tablets and hence improves dissolution. Microcrystalline cellulose, cross-linked 
carboxy methylcellulose, cross-linked polyvinyl pyrrolidones and partially substituted 
hydroxy propyl cellulose, absorb water and swell due to capillary action and are 
considered as effective disintegrant in the preparation of fast dissolving tablets.  
6) Sugar-based excipient:  
Sorbitol, Mannitol, dextrose, Xylitol, Fructose, Maltose, Isomalt, and Polydextrose 
have been used as bulking agents. Because of their high aqueous solubility and 
sweetness, which impart a pleasing mouth feel and good taste masking, nearly all 
formulations for rapidly dissolving tablets contain sugar-based materials.  
7)  Direct compression:10 
  Conventional equipment,  commonly  available excipients and  a limited 
number of processing steps are involved in direct compression. Disintegrant 
efficiency is strongly  affected by  tablet  size and  hardness. Large and hard tablet 
have disintegration time more than that  usually required. As a  consequence, product  
with  optional  disintegration  properties  often have  medium   to  small size and/or 
high friability and low hardness.  Disintegrants  have  major  role  in  disintegration  
and  dissolution  of  mouth  dissolving  tablets  made  by  direct  compression.  
Disintegration efficiency  is  based  on  force  equivalent  concept, which  is combined 
measurement of  swelling  force  development and  amount of water absorption.  The 
simultaneous presence of  disintegrant with  high  swelling  force called  
disintegrating  agent and  substances  with  low  swelling  agent are claimed to be  key  
factor for rapid  disintergration  of  tablet; which  also  offer  physical  resistance. 
8)  Mass extrusion:11 
            The  technology involves  softening the  active  blend  using  the  solvent  
mixture of  water soluble  polyethylene  glycol,  using menthol  and  expulsion of  
softened mass  through  the  extruder or syringe to  get  a  cylinder  of the  product  
into  even  segments using  heated  blade to from tablets.  The dried cylinder can  also  
be  used  to  coat  granules  of  bitter tasting  drugs  and  thereby  making  their bitter  
taste. 
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1.3 PATENTED TECHNOLOGIES5,9,12 
1) Zydis:-  
This technology converts the mixture of active ingredient and water dispersible carrier 
materials into open matrix network that disintegrates rapidly using freeze-drying 
process. The network is highly porous solid foam, which allows rapid penetration of 
liquid and facilitates quick disintegration of the dosage unit. In Zydis technology, 
drug is added to a solution of carrier material (preferably gelatin) to obtain dispersion, 
and the dispersion is filled into preformed pockets of blister pack by automatic means, 
and freeze dried to produce the final dosage form.  
2) Orasolv:-  
This system essentially makes tablets that contain the taste masked active ingredients 
and an effervescent disintegrating agent, which on contact with saliva, rapidly 
disintegrates and released the active ingredient. The tablets are made by direct 
compression at very low compression forces in order to minimize oral dissolution 
time. The tablets produced are soft and friable.  
  Durasolv:-                                                                                                                             
The   tablet  made  by   this  technology  consists  of  drug, fillers   and  lubricant. 
Durasolv tablets  are prepared  by using  conventional tableting  equipment and have 
good  rigidity. It is an appropriate  technology for products  requiring low amount of  
active ingredients.  
3) Flash dose:-  
Flash dose tablets consist of self-binding shear form matrix termed as “floss”. Shear 
form matrices are prepared by flash heat processing and are of two types.  Single floss 
or Unifloss, consisting of a carrier, and two or more sugar alcohols, of which one is 
xylitol. Dual floss consists of a first shear form carrier material (termed “base floss”, 
contains a carrier and at least one sugar alcohol generally sorbitol), and a second shear 
form binder matrix (“binder floss”, contains a carrier and xylitol).  
 In flash heat process, the feed stock (carbohydrates including sugars and 
polysaccharides) is simultaneously subjected to centrifugal force and to a temperature 
gradient, resulting in discrete fibers. The preformed matrices obtained are partially 
crystallized and have good self-binding and flow properties. The so formed matrices 
are complex crystalline structures with high specific surface area and result in rapid 
dissolution rate of the drug. The shear form matrix is blended with drug and other 
                                                                                                     Introduction                          
         
                                                                                                                                         Page 20                           
tableting ingredients, and compressed into tablets using conventional tableting 
equipment. Flash dose tablets are soft, friable and hygroscopic dosage forms, which 
require specialized packaging.  
4) Wow tab:-  
This process uses a combination of low mouldability saccharine (rapid dissolution) 
and high mouldability saccharine (good binding property) to obtain a rapidly melting 
strong tablet. The active ingredient is mixed with a low mouldability saccharine (e.g. 
lactose, mannitol) and granulated with a high mouldability saccharine (e.g. maltose, 
sorbitol) and compressed into tablets.  
5) Flash tab:-  
This technology involves the preparation of rapidly disintegrating tablet, which 
consists of an active ingredient in the form of micro crystals. Drug micro granules 
may be prepared by using the conventional techniques like coacervation, micro 
encapsulation, extrusion-spheronization or simple pan coating method. The micro 
crystals or micro granules of the active ingredient are added to the granulated mixture 
of excipient prepared by wet or dry granulation, and compressed into tablets.  
6)  Oraquick ( kv pharmaceutical company inc.):13 
               The Oraquick  mouth dissolving  tablet formulation utilized a patent taste 
masking technology. KV pharmaceutical claims its microsphere technology, known 
as micromask, has superior mouth feel over taste masking alternatives. The taste 
masking process does not utilize solvents of any kind, and therefore leads to faster 
and more  efficient production. Also lower heat of production than alternative fast 
dissolving  technologies make oraquick  appropriate for heat sensitive drugs. 
Oraquick claims quick dissolution in a matter of seconds, with good taste masking. 
7)  Shearform technology:14-16 
            The Shearform technology is based on preparation of floss  that also  known as 
shearform  matrix,  which is  produced by  subjecting a  feedstock  containing  sugar 
carrier to  flash heat processing.  In this  process,  the sugar is  simultaneously  
subjected to create  an  internal flow condition,  which permits  part of it  to move 
with  respect  of the mass.  The flowing mass  exists through the spinning head  that 
flings  the floss,  the floss  so produced  is amorphous in nature,  which is further 
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chopped  and re-crystallized by  various techniques to  provide uniform  flow  
properties  and thus  facilitate blending. 
             The crystallized matrix is then blended with other tablet excipients  and  an 
active  ingredient and  other excipients can be  blended with floss  before carrying out 
re-crystallization.  The shearform  floss,  when blended with the  coated or uncoated 
microsphere, is  compressed  into tablets on  slandered  tabletting   equipment.  
8) Ceform technology:17-19 
              In  Ceform  technology  microsphere  containing  active drug  ingredient are  
prepared.  The essence  of  Ceform microsphere  manufacturing  process involves  
placing   a drug powder,  containing  substantially  pure drug  material  or  a special 
blend of drug material  plus  other  pharmaceutical  compounds  and excipients  into  
precision  engineered,  and  rapidly spinning  machine.  The centrifugal force  of the 
rotating head of Ceform machine  throws the drug  blend at high speed  through  
small,  heated openings.  The carefully  controlled temperature  of the  resultant 
microburst  of heat liquefies the blend  to form  a  sphere without adversely  affecting  
the drug stability.  The  microsphere  are then  blended and/or  compressed into the 
pre-selected  oral delivery dosage form.  The ability to simultaneously process both  
the drug  and excipients  generates  a unique  micro environment in  which  materials 
can be  incorporated  into the  microsphere that can  alter  the characteristics  of the  
drug  substance,  such as  enhancing  solubility  and  stability.  The  microsphere can  
be  incorporated  into  a wide  range of  fast dissolving  dosage forms  such  as EZ 
chew,  spoon dose as well as  conventional tablets.  
1.4 TASTE MASKING20,21 
Taste of a pharmaceutical product is an important parameter governing compliance. Bitter 
tasting drugs, drugs with an objectionable odour, or drugs that are sensitive to oxygen or 
atmospheric moisture may require encapsulation or entrapment prior to compression. Hence 
taste masking of oral pharmaceuticals has become important tool to improve patient 
compliance and the quality of treatment especially in pediatrics. Hence formulation of taste 
masked products is a challenge to the pharmacist. 
As more than 50% of pharmaceutical products are administered orally, undesirable 
taste is one of the important formulation problems that can be encountered with 
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certain drugs. Oral administration of bitter drugs with acceptable level of palatability 
is a key issue for health care providers especially with pediatrics and geriatric patient. 
Thus, elimination or reduction of bitterness is an important issue during design of oral 
pharmaceutical formulations. 
 A major component of success in orally disintegrating tablets (ODT) is good taste. If 
the product taste good, ODT formulations are emerging and gaining popularity in the industry 
and have a significant impact on patients of all ages. ODT tablets dissolve or disintegrate in 
the oral cavity in a relatively short time and do not need to be swallowed with water. This has 
made taking medication easier, especially for children and the elderly who have traditionally 
had difficulties in swallowing more conventional dosage forms. The single most significant 
issue with ODT is the bitterness of the drug that can be exposed, and combining this with the 
right flavors/sweetness levels will result in a superior product. 
Four fundamental sensations of taste have been described : 
 Sweet and salty, at tip. 
 Sour, at sides. 
 Bitter, at back. 
1.5 METHODS OF TASTE MASKING 21 
Various techniques available for masking bitter taste of drugs include: 
1.5.1 Taste masking with ingredients such as flavors, sweeteners and amino acids. 
1.5.2 Taste masking by polymer coating. 
1.5.3 Inclusion Complexes with β-Cyclodextrin Derivative. 
1.5.4 Taste masking by ion-exchange resins. 
1.5.5 Miscellaneous taste masking technologies. 
1.5.1 Taste masking with ingredients such as flavors, sweeteners and amino 
acids. 21 
Addition of flavors and sweeteners is the simplest approach for taste masking 
especially in pediatric formulations. Besides taste masking, flavors can also improve 
aesthetic appeal of the products. However this approach is not very successful for 
highly bitter and highly water soluble drugs.  
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Discover the flavoring agent best suited to mask an unpleasant taste is often a very 
empirical matter. Experience and experimentation have produced some general 
guidelines regarding the type of flavor best suited to mask a given taste.  Such 
recommendations are listed in Table 1. 
Table 1 : List of flavors21 
Taste Masking flavor 
Salty 
 
                  Cinnamon, Raspberry, Orange, Apple, Butterscotch, 
Glycyrrhiza (Licorice) syrup. 
Sweet                    Fruit berry, Vanilla, Acacia syrup 
Bitter 
 
                   Cocoa, Chocolate- Mint, Wild Cherry, Walnut 
                   Glycyrrhiza (licorice), Eriodictyon, Raspberry syrup. 
Sour                    Fruit citrus, cherry syrup 
 
Sweeteners: Aspartame is a prominent sweetener for bitterness reduction.  A concentration of 
as small as 0.8% was effective in reducing the bitterness of a 25% formulation of 
acetaminophen.  
 Artificial sweeteners like neohesperidine dihydrochalone which is a bitterness 
suppressor and flavor modifier, elicits a very intense sweet taste. Vitamins containing 
oral solutions are rendered bitterness free by adding sugars, amino acids, and apple 
flavors. 
1.5.2. Taste masking by polymer coating21 
Coating is an extremely useful technique for a number of applications, but its major 
application is in masking the unpleasant taste. Various inert coating agents can be used to coat 
bitter drugs. They include starches; polyvinyl pyrrolidones (povidone) of various molecular 
weights, gelatin, methylcellulose, hydroxymethylcellulose, microcrystalline cellulose and 
ethyl cellulose. These coating agents simply provide a physical barrier over the drug particles. 
One of the most efficient methods of drug particle coating is the fluidized bed coating. In this 
approach, powders as fine as 50 mm are fluidized in an expansion chamber by means of 
heated, high-velocity air, and the drug particles are coated with a coating solution introduced 
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usually from the top as a spray through a nozzle.  Increasing the length of the coating cycle 
can increase coating thickness.  
1.5.3. Inclusion Complexes with β-Cyclodextrin Derivative22 
In inclusion complex formation, the drug molecule fits into the cavity of a complexing 
agent, i.e., the host molecule, forming a stable complex. The complexing agent is 
capable of masking the bitter taste of drug by either decreasing its oral solubility on 
ingestion or decreasing the amount of drug particles exposed directly to taste buds, 
thereby reducing the perception of bitter taste. This method is most suitable only for 
low dose drugs. Vander-vales forces are mainly involved in inclusion complexes. β -
Cyclodextrin is the most widely used complexing agent for inclusion type complexes. 
It is a sweet, nontoxic, cyclic oligosaccharide obtained from starch. 
 The strong bitter taste of carbetapentane citrate was reduced to approximately 
50% by preparing a 1:1 complex with β-Cyclodextrin. Palatable ibuprofen solutions 
are prepared by forming inclusion complexes with Hydroxy Propyl β-Cyclodextrin 
respectively. The complex masked the bitter component but created a sore taste that 
was masked by sweeteners. 
1.5.4. Taste Masking by Ion-Exchange Resins23 
Ion exchange resins are solid and suitably insolubilized high molecular weight 
polyelectrolyte’s that can exchange their mobile ions of equal charge with the surrounding 
medium reversibly and stochiometrically. They are available in desired size ranges. Bitter 
cationic drugs can get adsorbed on to the weak cation exchange resins of carboxylic acid 
functionally to form the complex which is not bitter. Further resinates can be formulated as 
lozenges, chewing gum, suspension or dispersible tablet and mask the taste. Drugs are 
attached to the oppositely charged resin substrates or resinates through weak ionic bonding so 
that dissociation of the drug-resin complex does not occur under salivary pH conditions. This 
suitably masks the unpleasant taste and odors of drugs.  
Ion exchange resins can be classified into four major groups.23 
1.  Strong acid cation exchange resin: Eg - Amberlite IRP-69, Indion-224. 
2.  Weak acid cation exchange resin: Eg. - Amberlite IRP-65, Indion-234S, 
      Indion-204  
3.  Strong base anion exchange resin:  Eg. - Amberlite IRP-276. 
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4.  Weak base anion exchange resin: Eg. - Dimethylamine resin 
 
1.6 ROLE OF DISINTEGRANT:24 
       For tablets,  it is  necessary to overcome  the  cohesive strength introduced  into the mass  
by compression.  Therefore, it is  usual practice to incorporate  excipients called disintegrant,  
which will  include during formulation.  Tablets containing a disintegrant break up  rapidly in 
the  water because of the sudden  and immediate application of the  stress.  However,  when a  
tablet containing  such  disintegrant is  exposed to  water  stress is  built  up  slowly  and  
tablet absorbs some of the  strain. For most  tablets the most important step is the  breakdown 
of the tablet into  the smaller particles  or  granules,  this step is  known as  disintegration.  
 Superdisintegrant  are the  agents added to tablet  and some encapsulated  
formulations to promote the breakup of the tablet and capsule “slugs’ into smaller fragments 
in an aqueous environment there by increasing the available surface area and promoting a 
more rapid release of the drug substance. They promote moisture penetration and dispersion 
of the tablet matrix. Tablet disintegration has received considerable  attention as  an essential  
step in  obtaining  fast  drug release. 
 
          
                             Figure 5 : Mechanism of Action of Superdisintegrants 
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Mechanism action of disintegrants 
 By capillary action  
 By swelling 
 Due to deformation 
 Due to disintegrating particle/particle repulsive forces 
 Because of heat of wetting 
 Due to release of gases 
 By enzymatic action 
 
Capillary action: Disintegration  by capillary action is always the first step. When we put the 
tablet into suitable  aqueous medium, the medium  penetrates into the tablet and replaces the 
air adsorbed  on the particles, which weakens the intermolecular bond and breaks the tablet 
into fine particles. Water  uptake by tablet depends upon hydrophilicity  of the  drug 
/excipient  and on  tabletting  conditions.  For these types of disintegrants, maintenance of  
porous  structure  and low interfacial  tension towards  aqueous  fluid is  necessary  which  
helps in  disintegration by creating a hydrophilic  network around  the drug  particles25. 
 
Swelling: Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling. Tablets  with high  porosity  show poor disintegration due to lack of 
adequate swelling force. On the other hand, sufficient swelling force is exerted in the tablet 
with low porosity. It is worthwhile to note  that if  the  packing fraction is very high, fluid is 
unable to penetrate in the tablet and  disintegration is again slows down25. 
 
Due to deformation: Hess  had proved  that during tablet  compression, disintegrated 
particles get deformed and  these deformed particles get into their normal structure 
when they come in contact with aqueous media or water.  Occasionally, the swelling capacity 
of starch was improved when granules  were extensively  deformed during 
compression13,25. 
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Figure 6 :   Disintegration of Tablet by Wicking and Swelling 
              
Figure 7:  Disintegration by Deformation and Repulsion 
 
Disintegration of tablet by repulsion: Another  mechanism of disintegration attempts to 
explain the swelling  of tablet  made with ‘non-swellable’ disintegrants. 
Guyot- Hermann  has proposed a particle  repulsion theory  based on the observation that no 
swelling particle also  causes disintegration of tablets. The electric repulsive forces  between  
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particles are  the mechanism  of disintegration  and water is required for it.  Researchers  
found that  repulsion is secondary to wicking13,25. 
Heat wetting: When disintegrants with exothermic  properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps  in disintegration  of 
tablet. This explanation, however, is  limited to only a few  types of  disintegrants and cannot 
describe the action of  most modern  disintegrating  agents25. 
Due to release of gases: Carbon dioxide released  within tablets on wetting due to interaction 
between  bicarbonate and carbonate with citric acid or tartaric acid. 
The tablet disintegrates due to generation of pressure within the tablet. This effervescent 
mixture is used when pharmacist needs to formulate very rapidly dissolving tablets or fast 
disintegrating  tablet. As these  disintegrants are highly sensitive to small changes in  
humidity level and temperature, strict control of environment is required during  
manufacturing of the tablets. The effervescent blend is either added  immediately prior  to 
compression  or can be added  in to two separate fraction of formulation25. 
By enzymatic action: Here, enzymes present in the body act as disintegrants. These enzymes 
destroy the  binding  action of  binder  and helps  in disintegration.  Actually due to swelling,  
pressure  exerted in the  outer  direction  or radial direction, it causes tablet to burst or the  
accelerated  absorption of  water leading to  an enormous increase in the volume of  granules  
to promote  disintegration25. 
Methods of Incorporating Disintegrants into Tablets26,27,28: 
There  are two  methods of  incorporating  disintegrating  agents into the tablet as described 
below  
 Internal Addition (Intragranular): In Internal  addition method, the disintegrant is 
mixed with other powders  before  wetting the  powder  mixtures  with the 
granulating fluid. Thus the  disintegrant is incorporated  within the granules. 
 External Addition (Extragranular) : In external addition method, the disintegrant is 
added to the sized granulation  with mixing  prior to compression. 
 Partly Internal and External: In this method, part of disintegrant can be added 
internally  and  part externally.  This results in  immediate disruption  of the tablet  
into previously  compressed  granules while  the disintegrating  agent within the 
granules  produces additional  erosion of the  granules to the original powder 
particles. 
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2.AIM AND OBJECTIVES 
 
Dexibuprofen is an non-steroidal anti-inflammatory drug (NSAID) , a propionic acid 
derivative with analgesic and antipyretic properties.  Dexibuprofen,  (S(+)-ibuprofen)  is a 
pharmacologically active form and is more potent than Ibuprofen, which contains equal 
quantities of R(−)- and S(+)-enantiomers. It is a bitter drug. Dexibuprofen inhibits 
cyclooxygenases and activates peroxisome proliferators-activated receptors; both of these 
actions result in reduced inflammation. 
 The aim of present work  was  to design and evaluate orally disintegrating tablets 
(ODTs) containing Dexibuprofen using superdisintegrants and wherein its bitter taste is also 
masked.   
            OBJECTIVES OF THE RESEARCH WORK   
            Broadly, the work would endeavour  to achieve  the following objectives: 
1. Selection of a model non-steroidal anti-inflammatory drug (NSAID), (Dexibuprofen) 
based on pharmacokinetic parameters suitable for formulating into an ODT. 
2. Selection of appropriate excipients including superdisintegrants (crosscarmellose 
sodium, crospovidone, sodium starch glycollate) to develop the dosage form based on 
physico-chemical properties and compatibility of the Active Pharmaceutical 
Ingredient (API) and excipients.  
3. Preparation of standard calibration curve for Dexibuprofen. 
4. Formulation development of fast disintegrating tablet  by  direct  compression 
method. 
5. Characterization and evaluation of the formulations 
I.  Pre-compression parameter: 
     a.  Drug  excipient  compatibility  studies:   Comparison  of  drug   and   its  
          combination with various polymers with FTIR. 
     b. Evaluation of powder: Bulk density, Tapped density, Angle of repose,    
         compressibility index. 
II. Post compression parameters:  
     a. Appearance and its dimension measurements 
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     b. Weight variation test 
     c. Wetting time 
     d. Water absorption ratio 
     e. Hardness test 
     f. Friability test  
6.  In vitro evaluation of formulation 
    a. In vitro disintegration studies 
    b. In vitro dissolution studies and curve fitting analysis 
7. Optimization of the dosage form based on evaluated parameters to meet official &/or 
pharmacokinetic specifications. 
8. Stability Study of the formulation as per ICH guidelines. 
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PLAN OF WORK 
 
1. Literature review 
2. Selection of drug and excipient 
3. Preformulation study. 
 Organoleptic characteristics 
 Solubility of drug 
 Particle size distribution.   
 Physico-mechanical characterization. 
 Moisture content.  
 Drug potency Calculaion. 
 Drug-excipient Compatibility study. 
4. Formulation of tablets by Direct Compression technique using Superdisintegrants. 
5. Evaluation of the formulated tablets. 
 Thickness 
 Hardness and friability 
 Disintegration time 
 Weight variation 
 Wetting time 
 Water absorption ratio 
 In vitro Dissolution 
6.  Optimization of Selected formula. 
7. Stability study of optimized formulation. 
8. Result and discussion.
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3. REVIEW OF LITERATURE 
 
Fukami et al.,29. was prepared rapidly disintegrating tablets using glycine as a disintegrant. 
They evaluated the disintegration behavior of tablets in oral cavity containing carboxymethyl 
cellulose showed the least wetting time 3 seconds with 4 kg hardness and showed the fastest 
disintegration due to excellent wetting property. They also studied the effect of ethanzamide 
and ascorbic acid on disintegration time. Result shows that ethanzamide has no effect on 
disintegration property. However, the disintegration time increases with ascorbic acid.  
 
Moen and Keating 30   had developed a new fast-disintegrating Sumatriptan tablet with the 
goal of speeding absorption and onset of effect compared with standard Sumatriptan tablets. 
Compared with placebo, pain relief was significantly greater with Sumatriptan fast 
disintegrating tablets 100mg at 25 and 17 minutes following administration and with 
Sumatriptan fast disintegrating tablets 50mg at 50 and 30 minutes following administration, to 
severe migraine.  
 
Mizumoto et al.,31 was prepared novel fast disintegrating tablets using commonly used sugar 
as low and high compressible categories. They improved the compressibility of low 
compressible saccharides by coating the granules with high compressible saccharides to 
enable fast disintegration and changed the crystal habit by the process and achieved sufficient 
hardness. 
 
Shirwaikar and Ramesh 32 had formulated Atenolol using super disintegrant such as sodium 
starch glycollate, croscarmellose sodium (Ac-Di-sol) and crospovidone. Dry granulation 
method was used to prepare tablets. Various physical parameters considered are water uptake 
studies, In vitro release and stability profile. Ac-Di-sol proved to be best of the three super 
disintegrant and showed the highest water uptakes. There was no change after stability study 
of the tablets. 
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Udupa et al.,33 was reported the preformulation, preparation and evaluation of Nimesulide 
dispersible tablets by direct compression method. The tablets were prepared using 
microcrystalline cellulose as directly compressible vehicle, starch and sodium starch 
glycollate combination as super disintegrant. The formulations were evaluated for hardness, 
weight variation, uniformity of dispersion, drug content disintegration time, dissolution rate 
and stability studies. The optimized formula showed less disintegration time and more 
dissolution than marketed product. 
 
Mishra et al.,34 had developed Ora-Solv technology. In this system active medicament is taste 
masked by using effervescent disintegrating agent. Tablets was made by direct compression 
technique at low compression force in order to minimize oral dissolution time. 
 
Baldi and Malfertheiner 35 was prepared Lansoprazole fast disintegrating tablet a new, 
patient-friendly and more convenient formulation of Lansoprazole, which can be taken with 
or without water. It represents an innovative drug delivery system, comprising enteric-coated 
micro granules of Lansoprazole compressed with an inactive, rapidly dispersing matrix to 
form a tablet. Alternatively, the tablet can be swallowed with a drink of water. Studies have 
shown that the bioavailability of Lansoprazole fast disintegrating tablet is comparable to 
Lansoprazole capsules, at both 15 and 30 mg doses. 
 
Ahmed et al.,36 had developed Ketoprofen tablets which dissolve rapidly in the mouth, 
therefore needing not to be swallowed. The solubility and dissolution rate of poorly water-
soluble Ketoprofen was improved by preparing lyophilized tablets (LT) of Ketoprofen using 
freeze-drying technique. Results obtained from dissolution studies showed that lyophilized 
tablets of Ketoprofen significantly improved the dissolution rate of the drug compared with 
the physical mixture and the plain drug. 
 
Seager 37 was studied Zydis formulation which is a unique freeze dried tablet in which drug 
was physically entrapped or dissolved within the matrix of fast dissolving carrier material. 
When a zydis unit was put into the mouth, the freeze dried structure disintegrates 
instantaneously and does not require water to for swallowing. 
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Ohkuma et al.,38 was prepared and evaluated a fast disintegrating tablet containing Nicordial 
loaded particles with 1-4% croscarmellose sodium in addition to D-mannitol and lactose was 
prepared and examined. The results suggested that formulation had masking effect against the 
bitter taste and irritation of the drug. 
 
Shenoy et al.,39 had developed fast dissolving tablets of Diclofenac sodium using direct 
compression after incorporating super disintegrant such as cross linked carboxy methyl 
cellulose, sodium starch glycolate and cross linked crospovidone in different concentrations 
and evaluated the effect of their concentrations on the characteristics of fast dissolving tablets 
mainly in terms of disintegration time and dissolution rate. 
 
Mutasem et al.,40 was studied the effect of increase in Epinephrine in fast disintegrating 
tablets. They used microcrystalline cellulose and L-hydroxy propyl cellulose as a diluent in 
the ratio (9:1) and direct compression was employed in the preparation of the tablets. Result 
shown that linear increase in compression force resulted in linear increase in disintegration 
and wetting time of formulations without epinephrine and exponential increase in 
disintegration time and wetting time for tablets containing Epinephrine. 
 
Mishra et al.,41 was assessed the suitability of spray dried excipient base in the formulation of 
oral disintegrating tablets of Valdecoxib and Metoclopramide. Superdisintegrants (such as 
Ac-Di-Sol, Kollidon CL, sodium starch glycolate), diluent (mannitol) along with sweetening 
agent (aspartame) were used in the formulation of tablets. Using the same excipient, the 
tablets were prepared by direct compression and were evaluated in the similar way. Maximum 
drug release and minimum disintegrating time were observed with Kollidon CL excipient 
base as compared to tablets prepared by direct compression, showing the superiority of the 
spray dried excipient base technique over direct compression technique.  
 
Chandrasekhar et al.,42 was reported preparation and evaluation of Nimesulide dispersible 
tablet using primo gel as dispersing agent with starch, lactose and dicalcium phosphate as 
diluents. The tablets were prepared by wet granulation method and compared with 
commercial dispersible tablets. The formulation with starch and lactose as diluents showed 
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fast and rapid dissolution than conventional tablets; whereas the tablets with dicalcium 
phosphate as diluent showed less dissolution rate. 
Nayak and Gopala43 had formulated fast dissolving tablets of Promethazine theocholate. 
They used three different methods for the preparation of tablets, effervescent melt method 
using citric acid, sodium bicarbonate. Second method was by grinding microcrystalline 
cellulose and mannitol and compression. Third method was by adding sugars like high mould 
ability and low mould ability sugars. They confirmed that effervescent are better forms for 
mouth feel and better release. 
 
Bhagawati et al.,44 had formulated dispersible tablet of Cefixime with various disintegrates 
like croscarmellose sodium, sodium starch glycollate, crospovidone and using starch and PVP 
K30 as binders. They used direct compression as the method of preparation of tablets. Even 
though the mean disintegration time decrease with sodium starch glycollate and 
Crospovidone. In comparison with croscarmellose sodium it is impediment they concluded 
that croscarmellose sodium is best of the three. 
 
Chaudhari et al.,45 had masked the bitter taste of the drug by complexing with eudragit E100 
at different concentrations of 1:1 to 1:10. Mouth dissolving tablets were prepared by using 
Ac-Di-Sol and polyplastadone as Superdisintegrants. They used direct compression method 
for preparation of tablets. They found that all the formulations showed faster release 
compared to marketed products that show 20 min for the 100% all formulations showed 81% 
to 87% release of the drug in first 2 minutes. Stability studies showed that there is a slight 
increase in disintegration time and decreased in dissolution may be due to formation of lumps 
of eudragit. 
 
Adel et al.,46 was prepared Tenoxicam fast disintegrating tablets with solid disposition on 
super disintegrant and used camphor as sublimating agent to prepare the porous structure. 
They found the tablets with drug excipient ratio 1:9 with camphor showed fastest dissolution 
rate. The in vivo studies showed that the formulation having sodium starch glycollate have 
higher dissolution when prepared with camphor sublimation 
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Sreenivas et al.,47 was prepared Ondansetron hydrochloride mouth disintegrating tablets 
using various disintegrant like crospovidone, croscarmellose sodium, pre-gelatinized starch, 
sodium starch glycolate and low-substituted hydroxyl propyl cellulose (L-HPC) in 5% and 
10% concentrations and by direct compression method. Result shows that tablets containing 
10% disintegrant concentration of crospovidone and croscarmellose sodium were best for 
Ondansetron hydrochloride mouth disintegrating tablets. 
 
Avinash et al.,48 had formulated highly porous mouth dissolving tablets of Domperidone by 
using meltable binder polyethylene glycol 4000, mannitol, Camphor, ammonium bicarbonate 
that sublimes rapidly. The later is removed from the tablets by sublimation process after 
compressing. Two of the formulations having 40% w/w of ammonium bicarbonate and 20% 
of camphor respectively emerged to be the most satisfactory exhibiting the disintegrating time 
of 19.661.53 seconds and 21.33 1.16 seconds and other parameters were found to be 
satisfactory. 
 
Patel et al.,49 was selected crospovidone from three super disintegrant as the prime study by 
considering wetting time and disintegrating time. In this work Rofecoxib tablets were 
prepared by wet granulation method.  They conducted optimizing the concentration of 
crospovidone and concluded 10 % concentration as the best concentration for preparing fast 
disintegrating tablets. To these results 32 factorial design was employed taking concentration 
of crospovidone and mannitol as independent variable and wetting time and disintegration 
time as the dependent variables. The best formula was compared with two marketed 
formulations and the obtained formula showed better dissolution than marketed products. 
 
Mahajan et al.,50  was prepared mouth dissolving tablets of Sumatriptan sulphate by using 
disintegrant sodium starch glycolate, carboxy methyl cellulose and treated agar by direct 
compression. The tablets disintegrate by In vitro and In vivo methods in 10 minutes. The 
formulation containing combination of sodium starch glycolate and carboxymethyl cellulose 
was found to give the best results when compared to carboxy methyl cellulose and agar. 
 
Patel et al.,51 had formulated tablets of Piroxicam with PVP K30 and sodium lauryl sulphate 
with a view to increase its water solubility. Sodium lauryl sulphate is used in solid dispersion 
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with PVP K30 by solvent evaporation method. This solid dispersion was converted into 
tablets by using different disintegrating agents like sodium starch glycollate and 
crospovidone. 32 factorial designs were applied for the study and they found increase in 
dissolution with the super disintegrant concentration. 
 
Kuchekar et al.,52 was attempted to make mouth-dissolving tablets of Salbutamol sulphate 
and they employed 2n factorial design to select the super disintegrant from croscarmellose 
sodium, treated agar and sodium starch glycollate for the formulations preparations. Tablet 
was prepared by direct compression method. Result shown that formulations containing 
sodium starch glycolate showed excellent release compared to other formulations. Even at the 
lower concentrations. 
 
Chowdary and Hemavathi 53 had reported the formulation of Ibuprofen dispersible tablets 
by employing potato starch, primo gel, microcrystalline cellulose and pre-gelatinized starch. 
Tablets formulated employing primo gel as internal and external disintegrant and tablets 
formulated employing potato starch as internal disintegrant and primo gel and pre-gelatinized 
starch as external disintegrant fulfilled the entire official and other requirements of dispersible 
tablets. These tablets also gave rapid and higher dissolution rate then the formulated as well 
as conventional tablets. 
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3.2  DRUG PROFILE: 
 Name of the drug: Dexibuprofen 
Chemical structure: 
 
             
 
Chemical name:   (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid 
Empirical formula: C13H18O2  
Molecular weight: 206.28082  g/mol  
Introduction54 
Dexibuprofen is a non-steroidal anti-inflammatory agent (NSAIA) with analgesic and 
antipyretic properties. It is prescribed for moderate to severe pain such as 
dysmenorrhea, toothache, osteoarthritis.  
Physical properties55 
Dexibuprofen occurs as a  white, bitter powder. It melts at 76°C. It is  sparingly 
soluble in water and freely soluble in methanol, ethanol, Isopropyl alcohol, Ethyl 
acetate. Dissociation constant pKa of Dexibuprofen is 4.91.  
Stereochemistry56: Dexibuprofen, S(+)-ibuprofen, is a pharmacologically active 
form and is more potent than ibuprofen, which has equal quantities of R(−)- and S(+)-
enantiomers 
BCS Class:  II (low soluble and highly permeable) 
Stability:  Stable under ordinary conditions. 
Analytical methods55 
A number of analytical methods have been reported for the analysis of Dexibuprofen. 
These include Ultra violet Spectrophotometric methods, HPLC methods, GC methods 
and GC/MS method.   
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Mechanism of Action55 
Dexibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme involved in 
prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects 
are believed to be due to inhibition cyclo-oxygenase-2 (COX-2) which decreases the 
synthesis of prostaglandins and formation of thromboxanes involved in mediating 
inflammation, pain, fever and swelling. Antipyretic effects may be due to action on 
the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and 
subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side 
effects of Dexibuprofen including GI ulceration. 
 Pharmacokinetics57 
Absorption 
Bioavailability 
Rapidly absorbed from the GI tract following oral administration; bioavailability averages 
approximately 80%.Peak plasma concentrations usually occur within 2 to2.1  hours after oral 
administration. 
Distribution 
Dexibuprofen is distributed in the body by binding to human plasma proteins at therapeutic 
concentrations 
Plasma Protein Binding 
Highly bound to plasma protein (90-99%) and site II of purified albumin, binding appears to 
be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml. 
Metabolism 
Extensively metabolized in the liver  by oxidation to 2 inactive metabolites:            (+)-2[4´-
(2-hydroxy-2-methylpropyl)phenyl]propionic acid and (+)-2-[4´-(2-
carboxypropyl)phenyl]propionic acid. Cytochrome P450 2C9 is the major catalyst in the 
formation of oxidative metabolites. Oxidative metabolites may be conjugated to glucuronide 
prior to excretion. 
 
Elimination Route 
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Dexibuprofen is rapidly metabolized and eliminated in the urine. 
Half-life 
2-4 hours. 
Pharmacodynamics: 
Dexibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-
inflammatory drug (NSAID), with analgesic and antipyretic properties. Dexibuprofen has 
pharmacologic actions similar to those of other prototypical NSAIAs, which  are thought  to 
act  through  inhibition of  prostaglandin  synthesis. 
Pharmacological effects58 
Dexibuprofen inhibits prostaglandin synthesis and formation of thromboxanes via 
blockade of cyclo-oxygenase (COX) enzymes. Dexibuprofen inhibits both COX-1 
and COX-2 synthesis.  
Indication: 
For symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and 
osteoarthritis. May be used to treat mild to moderate pain and for the management of 
dysmenorrhea. May be used to reduce fever. Has been used with some success for 
treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever 
and inflammation of pericarditis.  
Contraindications: 
 Hypersensitivity to Dexibuprofen to any other NSAID or to any of the 
excipients. 
 Active or suspected gastrointestinal ulcer or history of recurrent 
gastrointestinal ulcer Gastrointestinal bleeding or other active bleedings or 
bleeding disorders. 
 Active Crohns disease or active ulcerative colitis. 
 Severe heart failure. 
 Severe impaired hepatic function. 
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 Haemorrhage diathesis & other coagulation disorders or patients receiving 
anticoagulant therapy. 
 Third trimester pregnancy. 
Use with caution in: 
 Elderly people. 
 History of disorders affecting the stomach or intestines. 
 Inflammatory bowel disease such as Crohn's disease or ulcerative colitis. 
 Alcoholism. 
 Decreased kidney function. 
 Decreased liver function. 
 Heart failure. 
 High blood pressure (hypertension). 
 History of asthma. 
 History of allergies. 
 Diseases affecting connective tissue, e.g. systemic lupus erythematosus. 
 People with blood clotting disorders, e.g. haemophilia, or taking anticoagulant 
medicines. 
Precautions in: 
 People in whom aspirin or other NSAIDs, e.g. ibuprofen, cause allergic 
reactions such as asthma attacks, itchy rash (urticaria), nasal polyps, nasal 
inflammation (rhinitis) or swelling of the lips, tongue and throat (angioedema). 
 Active peptic ulcer or bleeding from the gut. 
 People who have had recurrent peptic ulcers or bleeding from the gut (two or more 
episodes). 
 People who have experienced bleeding or perforation of the gut as a result of 
previous treatment with an NSAID. 
 Flare-ups of Crohn's disease. 
 Flare-ups of ulcerative colitis. 
 Severe heart failure. 
 Severely decreased kidney and liver functions. 
 Third trimester of pregnancy. 
Pregnancy and lactation: 
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Certain medicines should not be used during pregnancy or breastfeeding. However, other 
medicines may be safely used in pregnancy or breastfeeding providing the benefits to the 
mother outweigh the risks to the unborn baby. Always inform your doctor if you are pregnant 
or planning a pregnancy, before using any medicine. 
 This medicine should not be used in the third trimester of pregnancy, as it may delay 
labour, increase the length of labour and cause complications in the newborn baby. It 
should only be used in the first and second trimesters if the potential benefit 
outweighs any potential risk to the foetus. Some evidence suggests that NSAIDs 
should also be avoided by women attempting to conceive, as they may temporarily 
reduce female fertility during treatment and may also increase the risk of miscarriage 
or malformations. Seek medical advice from your doctor. 
 This medicine may pass into breast milk, but in such small quantities that it is 
unlikely to harm the baby if the dose is low and treatment is short. However, as with 
all medicines, seek medical advice from your doctor before breastfeeding while 
taking this medicine. 
Side effects: 
Medicines and their possible side effects can affect individual people in different ways. The 
following are some of the side effects that are known to be associated with this medicine. Just 
because a side effect is stated here, it does not mean that all people using this medicine will 
experience that or any side effect. 
 Disturbances of the gut such as nausea, vomiting, diarrhoea, indigestion or abdominal 
pain. 
 Headache. 
 Dizziness. 
 Balance disorders involving the inner ear (vertigo). 
 Drowsiness. 
 Bleeding from the stomach or intestine. 
 Stomach or duodenal ulcer. 
 Retention of water in the body tissues (fluid retention), resulting in swelling 
(oedema). 
 Sensation of ringing or other noise in the ears (tinnitus). 
 Visual disturbances. 
 Confusion. 
 Depression. 
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 Abnormal reaction of the skin to light, usually a rash (photosensitivity). 
 Allergic reactions such as severe skin rashes, swelling of the lips, tongue and throat 
(angioedema) or narrowing of the airways (bronchospasm). 
 Kidney, liver or blood disorders. 
Drug Dosing: 
 The recommended dose of Dexibuprofen is 600-900 mg/day in 2-3 divided doses for 
pain and inflammation associated with musculoskeletal and joint 
disorders; Dysmenorrhoea in adult. 
 Maximum single dosage is 400mg Dexibuprofen 
 Dose may be increased up to 1200 mg Dexibuprofen per day in pts with acute 
conditions or exacerbations 
 Maximum daily dose is 1200mg in case of mild to moderate hepatic 
conditions. 
 
3.3 EXCIPIENTS PROFILE: 
Excipients: 
Substances, other than the active ingredient, which have been appropriately evaluated 
for safety and are included in a drug delivery system to provide support.  
The excipients used must have following characteristics- 
 They must be stable both physically, chemically and must be biologically inactive. 
 It must be free from microbial contamination 
 Excipients used in tablet formulation must be accepted by regulatory agencies and 
should meet the entire current regulatory requirement. 
 
Excipients used are : 
 Microcrystalline cellulose 
 Crospovidone 
 Croscarmellose sodium 
 Sodium starch glycollate 
 Aspartame 
 Colloidal silicon dioxide  
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 Magnesium stearate  
 
MICROCRYSTALLINE CELLULOSE59 
Synonyms                  :        Avicel PH, Celex, cellulose gel; Celphere;  
                                           CeoulusCrystalline cellulose; E460; Emcocel; Fibrocel; 
                                          Pharmacel; Tabulose; Vivapur 
Chemical names         :        Cellulose 
Empirical formula     :        (C6H10O5)n    n=220 
Molecular weight       :        36,000(approx) 
Structural formula    :    
 
 
 
 
 
 
Description                 :            Microcrystalline cellulose is purified, partially 
                                                depolymerized cellulose that occurs as a white,  
                                                odourless,  tasteless, crystalline powder composed of   
                                                porous particles 
Functional category  :            Adsorbent; suspending agent; tablet and Capsule  
                                                diluent; tablet disintegrant.    
Uses                            :             Adsorbent, Anti-adherent, Tablet disintegrant,  
                                                Tablet binder. 
Applications              :             Microcrystalline cellulose is widely used in  
                                                         pharmaceuticals, primarily as a binder/diluent in  
                                               oral tablet and capsule formulations. 
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                                               Microcrystalline cellulose is also used in cosmetics 
                                               and food products. 
 
CROSCARMELLOSE SODIUM60 
Synonyms  : Ac-Di-Sol, Crosslinkedcarboxymethylcellulose sodium, 
modified cellulose gum, Nymcell ZSX, Primellose, Solutab. 
Chemical name :  Cellulose sodium salt of carboxymethyl ether. 
Structural formula : 
 
    
Functional category :   Tablet and capsule disintegrant. 
Description  :  Croscarmellose sodium occurs as an odorless, white    
      Colored powder. 
Applications in pharmaceutical formulation or technology: 
 It swells 4-8 folds in 10 seconds. The cellulose derivative swells in two dimensions 
radially. In tablet formulations, croscarmellose sodium may be used in both direct 
compression and wet granulation processes. When used in wet granulation croscarmellose 
sodium is added to in both the wet and dry stages of the process so that wicking and swelling 
ability can both be utilized. 
 
 SODIUM STARCH GLYCOLLATE61 
Synonym  :  Carboxymethyl starch sodium salt, Explotab, Primojel, 
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Viva-star P. 
Chemical name :  Sodium carboxy methyl starch. 
Chemical structure : 
 
Description  : Sodium starch glycolate is a white to off-white, free 
flowing, practically tasteless, odorless powder. It consists of 
oval or spherical granules, 30-100ȝm in diameter. The 
diameter of the smaller granules ranging from 10-35 mcg.m. 
Functional category :  Tablet and Capsule Disintegrant 
Solubility  : Sparingly soluble in ethanol (95%), practically 
Insoluble in water. At a concentration of 2% w/v in cold 
water and settles in the form of a highly hydrated layer. 
Stability and storage : Tablets prepared with SSG have good storage  
Properties. It is stable and should be stored in a closed 
container to protect it from wide variations in humidity and 
temperature to avoid caking. The physical properties of SSG 
remain unchanged up to 4 years if stored at moderate 
temperatures and humidity conditions. 
Applications in pharmaceutical formulation: 
  Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
tablet and capsule formulations. It is commonly used in tablets prepared by either direct 
compression or wet granulation process. The usual concentration employed in a formulation 
is between 2-8%. Disintegration occurs by rapid uptake of water followed by rapid and 
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enormous swelling. Increasing the tablet compression appears to have no effect on 
disintegration time. 
 
CROSPOVIDONE62 
Structural formula: 
 
 
Synonyms                     :  Kollidon CL, Kollidon CL–M, Polyplasdone-XL, 
                                          Polyplasdone XL-10 
Chemical Name           :  1- ethenyl – 2- pyrrolidinone homopolymer 
Nonproprietary Name:  BP – Crospovidone 
                                          PhEur -Crospovidonum 
                                         USP NF – Crospovidone. 
Description                    : Crospovidone is white to creamy white finely divided, free 
                                          flowing practically tasteless / nearly odorless, hygroscopic  
                                          powder. 
Solubility                        : Practically insoluble in water and most organic solvents. 
Functional Category     : Tablet disintegrant.  
Application in Pharmaceutical Formulation: 
 Crospovidone is water insoluble tablet disintegrant and used at 2-8% 
concentration in tablets prepared by direct compression / wet and dry granulation 
methods. It exhibits high capillary activity and pronounced hydration capacity. Larger 
particles provide a faster disintegration than smaller particles. Crospovidone can also 
be used as a solubility enhancer with the technique of co-evaporation. It can also used 
to enhance the solubility of poorly soluble drugs. The drug is adsorbed on to 
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crospovidone in the presence of a suitable solvent and solvent is evaporated. This 
technique results in faster dissolution rate. 
 
ASPARTAME63 
Structural formula:  
 
 
 
Synonyms:  
Aspartyl phenyl amine Methyl Ester, Canderel, NutraSweet, Sancta, Tri-Sweet.  
Functional category:  
Sweetening agent.  
Applications:  
It is used as an intense sweetening agent in tablets powder mixes and vitamin preparations. It 
enhances flavor systems, can be used to mask some unpleasant taste, and has sweetening 
power of 180-200 times that of sucrose.  
Description:  
It occurs as white, almost odorless crystalline powder.  
Solubility:  
Slightly soluble in ethanol (95%), sparingly soluble in water. Solubility increases at higher 
temperature and more acidic pH  
Stability:  
It is stable in dry conditions. In presence of moisture, hydrolysis occurs. Degradation also 
occurs during prolonged heat treatment.  
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Storage conditions:  
Bulk material should be kept in a well-closed container and stored in a cool dry place.  
Incompatibilities:  
Incompatible with dibasic calcium phosphate & also with magnesium stearate.  
Safety:  
The WHO has set an acceptable daily intake of 40mg/kg body weight. 
 
COLLOIDAL SILICON DIOXIDE64 
Synonyms: 
Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, light anhydrous silicic 
acid,  silicic anhydride,  silicon dioxide fumed,  Wacker HDK. 
Chemical Name and CAS Registry Number: 
Silica [7631-86-9]. 
Empirical Formula and Molecular Weight: 
SiO2 - 60.08. 
Functional Category: 
Adsorbent ant caking agent, emulsion stabilizer, Glidant, suspending agent, tablet 
disintegrant, thermal stabilizer, viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology: 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food products. Its 
small particle size and large specific surface area give it desirable flow characteristics that are 
exploited to improve the flow properties of dry powders in a number of processes such as 
tableting. Colloidal silicon dioxide is also used to stabilize emulsions and as a thixotropic 
thickening and suspending agent in gels and semisolid preparations.  
Description: 
It is a light, loose, bluish-white colored, odorless, tasteless, no gritty amorphous powder. 
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Incompatibilities:  
Incompatible with diethylstilbestrol preparations.  
 
MAGNESIUM STEARATE65 
Synonyms: 
Magnesium octadecanoate, Octadecanoic acid, Magnesium salt, Stearic acid, Magnesium salt. 
Chemical Name and CAS Registry Number: 
Octadecanoic acid magnesium salt [557-04-0] 
Empirical Formula and Molecular Weight: 
C36H70MgO4   -   591.34 
Structural Formula:  
[CH3 (CH2)16COO]2 Mg 
Functional Category: 
Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25% to 5.0% w/w. It is also used in barrier creams. 
Description: 
Magnesium stearate is a very fine, light weight, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of Stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin. 
 
Incompatibilities: 
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Incompatible with strong acids, alkali’s, and iron salts. Avoid mixing with strong oxidizing 
materials. Magnesium stearate cannot be used in products containing aspirin, some vitamins 
and most alkaloidal salts. 
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4. METHODOLOGY  
 
4.1. MATERIALS AND EQUIPMENTS  
The following drug, excipient and chemicals were used for the formulation of ODTs. 
 
Table 2 :  List of Excipients and Chemicals 
 
 
 
Sr. 
No. 
Name Supplier of Materials Function 
1 Dexibuprofen Glochem Industries Ltd. 
Anti-inflammatory 
agent 
2 Microcrystalline cellulose Glochem Industries Ltd. Diluent 
3 Croscarmellose Sodium 
Loba  chemicals , Mumbai, 
India 
Super Disintigrant 
4 Sodium Starch Glycollate Meggle, Germany Super Disintigrant 
5 Crospovidone XL 10 
Colorcon Asia Pvt. Ltd. Goa, 
India 
Super Disintigrant 
6 Aspartame 
S.D.Fine Chemicals Ltd., 
Mumbai, India 
Sweetner 
7 
Colloidal Silicon Dioxide 
(Aerosil 200) 
Fine chemicals, Mumbai, 
India 
Flow improver 
8 Magnesium Stearate Meggle, Germany Lubricant 
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Table 3 :  List of Equipments 
Sr. No. Equipments Manufacturers 
1 Weighing balance Mettler Toledo (PG 403-S) 
2 pH meter Thermo electron corporation 
3 Mechanical stirrer Remi 
4 Halogen moisture balance Mettler Toledo 
5 Bulk Density Tester (USP) Electrolab (ETD -1020) 
6 Multi-station tablet compression machine Cadmach 
7 Hardness tester Vankel (VK 200) 
8 Friability tester Electrolab (EF-1W) 
9 Vernier caliper scale Mitutoyo 
10 Malvern particle size analyzer Malvern 
11 Stability chambers Thermolab 
12 Disintegration tester ED-2L Electrolab, Mumbai, Ind 
13 Dissolution test apparatus Labindia DS 8000 
14 UV Spectrophotometer 1700, Shimadzu, Japan 
15 Melting point apparatus Elico Ltd 
 
                                                                                                      Methodology                         
         
                                                                                                                                         Page 54                           
 
4.2. PREFORMULATION STUDY66,67 
Preformulation studies are the first step in the rational development of dosage form of 
a drug substance. The objective of preformulation studies are to develop a portfolio of 
information about the drug substance, so that this information useful to develop 
formulation. Preformulation can be defined as investigation of physical and chemical 
properties of drug substance alone and when combined with excipient. 
Preformulation investigations are designed to identify those physicochemical 
properties and excipient that may influence the formulation design, method of 
manufacture, and pharmacokinetic-biopharmaceutical properties of the resulting 
product.  
Followings test are performed for the Preformulation study. 
1. Organoleptic characteristics. 
2. Solubility of drug. 
3. Particle size distribution.   
4. Physico-mechanical characterization. 
5. Moisture content. 
6. Compatibility study. 
7. Drug potency calculation.  
 
1) Organoleptic Characteristics: 66 
The color, odour and taste of the drug were characterized and recorded using 
descriptive terminology. 
 
2) Solubility: 66 
The solubility of Dexibuprofen was determined as per BCS. The solubility was 
checked in 250 ml of 0.1N HCl and buffers within pH range 2 – 8 and in water. The 
highest amount of dose was accurately weighed and transferred in individual 
volumetric flask containing different solutions and sonicate for 30 minutes.                             
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Table 4 : Solubility studies 
    
 
 
 
 
 
 
 
 
 
 
 
3) Particle size distribution: 66 
By Malvern master seizer: 
For many active substances, particle size has an impact on powder flow; content 
uniformity and drug dissolution.  In order to assure consistent product quality, the 
particle size of the Dexibuprofen has been characterised. The particle size analyzed by 
Malvern master seizer is based on the principle of light scattering. The particles can 
be analyzed by two methods 
1. Dry method and 
2. Wet method 
In present study, the particles size was determined using dry method.   
 
Descriptive term Part of solvent required for 
one part of 
Solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30  
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000  
Practically insoluble or 
insoluble 
Greater than or equal to 10000 
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4) Physico-mechanical characterization 66 
 Bulk Density: 
It refers to packing of particles. Bulk density is used to determine the amount of drug that 
occupies the volume in g/ml. 
Procedure: Weighed quantity of Dexibuprofen was transferred into 100 ml measuring 
cylinder without tapping during transfer. The volume occupied by drug was measured. Bulk 
density was measured by using formula 
ρi   = m /Vi 
                    Where, m   = mass of the blend 
             Vi   = untapped volume 
 Tapped density:  
Weighed quantity of drug was taken into a graduated cylinder. Volume occupied by the drug 
was noted down. Then the cylinder was subjected to 500, 750 &1250 taps in tap density 
apparatus (Electro Lab USP II). According to USP, The blend was subjected for 500 taps. % 
Volume variation was calculated and subjected for additional 750 taps. % Variation is 
calculated. 
                                  ρt = m/Vt 
Where, Vt is tapped volume 
 
 Carr’s Index (Compressibility):  
The compressibility index and Hausner ratio are measures of the property of powder 
to be compressed. The packing ability of drug was evaluated from change in volume, 
which is due to rearrangement of packing occurring during tapping. It was indicated 
as Carr’s compressibility index was calculated as follows. 
Carr’s index = [Tapped density - Bulk density/Tapped density] X 100 
 
 Hausner Ratio:  
It is measurement of frictional resistance of the drug .The ideal range should be 1.2-1.5. It 
was determined by the ratio of tapped density and bulk density 
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Hausner Ratio = Tapped density / Bulk density 
 
 Angle of Repose: 
It is defined as the maximum angle that can be obtained between the free standing of powder 
heap and horizontal plane, which is given by the equation: 
                                                       = tan-1 h/r 
                                                Where,     = Angle of repose. 
              h   = Height of powder heap.  
              r   = Radius of the powder cone. 
Procedure: Weighed quantity of the drug was passed through a funnel kept at a height 2 cm 
from the base. The powder is passed till it forms a heap and touches the tip of the funnel. The 
radius was measured and angle of repose was calculated by using above formula.  
Table 5 :  Interpretation of powder flow 
Flow Character 
Compressibility 
Index (%) 
Hausner Ratio Angle of Repose () 
Excellent < 10 1.00–1.11 25-30 
Good 11–15 1.12–1.18 31-35 
Fair 16–20 1.19–1.25 36-40 
Passable 21–25 1.26–1.34 41-45 
Poor 26–31 1.35–1.45 46-55 
Very poor 32–37 1.46–1.59 56-65 
Very, very poor > 38 > 1.60 > 66 
 
5) Moisture content:67 
Moisture content was determined by halogen moisture analyzer. The Halogen 
moisture Analyzer works along the lines of the thermo gravimetric principle, i.e. the 
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sample's starting weight was recorded, and then a halogen radiator dries it while an 
integrated balance continuously records the sample weight. The total loss in weight 
was interpreted as the moisture content. Drug should have moisture content not more 
than 0.5 % w/w. 
  
6) Drug-Excipients Compatibility Study67 
Protocol for drug-excipient compatibility 
(a) Drug: Excipient Ratio: 
     Drug and excipient were taken in the ratios of 1:5 
(b) Storage condition: 
1. Initial sample at room temperature.  
2. 40°C/75 % RH for 4 weeks. 
 (c) Test to be performed: 
1. Physical observation. 
Procedure 
Dexibuprofen  and excipient were to be thoroughly mixed in predetermined ratio of 1:5 and 
passed through the 40# sieve. The blend was to be filled in transparent glass vials and closed 
with gray rubber stoppers and sealed with aluminum and kept into condition at 40°C/75 % 
RH for 4 week. Similarly Dexibuprofen was also subjected to same condition and time period 
as that of sample. 
 
Physical observation: 
Physical observation of each sample was carried out every week, for any color change or 
lumps formation. No color change or lumps observed in any of the preformulation sample 
kept for accelerated preformulation stability. 
 
FT-IR: 
Dexibuprofen and excipients are subjected to FT-IR spectral analysis. The drug was 
Compatible with excipients since no significant changes were observed in intensity and 
position of the peaks in the spectra. The results are shown in graph. 
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4.3. PREPARATION OF STANDARD CALIBRATION CURVE: 
 
Preparation of Phosphate buffer (pH 6.8)      
Take  0.94g  of  NaOH  and 6.845g  of  KH2PO4  in 1000ml volumetric flask,  and made upto 
the volume with distilled water to 1000 ml.   
Preparation of Standard Stock Solution of Dexibuprofen 
Transfer an accurately weighed quantity of about 10 mg of Dexibuprofen in working 
standard to a 10 ml volumetric flask. Add about 5 ml of pH 6.8 Phosphate buffer  and 
sonicate to dissolve. Make volume up to the mark with  pH 6.8 Phosphate buffer.  
Spectrophotometric scanning of Dexibuprofen 
Ȝmax was determined by subjecting the stock solution to UV Spectrophotometry   
between the wave lengths 200- 400 nm which gave a highest peak i.e. Ȝmax at       
221 nm. 
 
Preparation of working solution  
From standard stock solution respective concentrations of 3,6,9,12,15 and 18 µg/ml were 
prepared and analyzed by using UV Spectrophotometer at Ȝmax 221 nm and results were 
recorded. The calibration graph was plotted by taking concentration an x-axis and absorbance 
on y-axis. 
 
Table 6 :  Calibration Curve for Dexibuprofen 
Sr. No. Concentration(µg/ml) Absorbance at 221nm 
1 0 0 
2 3 0.158 
3 6 0.316 
4 9 0.468 
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5 12 0.597 
6 15 0.742 
7 18 0.909 
 
 
Figure 8 :  Calibration Curve for Dexibuprofen 
 
 
 
4.4 STRATEGIES FOR DEVELOPMENT OF ORODISPERSIBLE 
TABLET  
FORMULATION OF TABLETS: 
R² = 0.9991 
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Concentration 
Calibration curve 
Sr.  
No 
Ingredients 
F1 
(mg/tab) 
F2 
(mg/tab) 
F3 
(mg/tab) 
F4 
(mg/tab) 
F5 
(mg/tab) 
F6 
(mg/tab) 
1.    1. Dexibuprofen 100 100 100 100 100 100 
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Table 7 :  Composition of  formulation batch F1 to F6  
 
 
 
 
 
 
Table 8 : Composition of  formulation batch F7 to F12 
2.  
Microcrystalline 
cellulose 
91 91 91 87 87 87 
3.  Crospovidone 4 - - 8 - - 
4.  
Croscarmellose 
Sodium 
- 4 - - 8 - 
5.  
Sodium Starch 
Glycollate 
- - 4 - - 8 
6.  Aspartame 2  2 2 2  2 2 
7.  
Colloidal Silicon 
Dioxide 
1.5 1.5 1.5 1.5 1.5 1.5 
8.  
Magnesium 
Stearate 
1.5 1.5 1.5 1.5 1.5 1.5 
 Net Total 200.00 200.00 200.00 200.00 200.00 200.00 
Sr. 
No 
Ingredients 
F7 
(mg/tab) 
F8 
(mg/tab) 
F9 
(mg/tab) 
F10 
(mg/tab) 
F11 
(mg/tab) 
F12 
(mg/tab) 
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4.5 PROCEDURE:  
      
1.  Dexibuprofen 100 100 100 100 100 100 
2.  
Microcrystalline 
cellulose 
83 83 83 79 79 79 
3.  Crospovidone 12 - - 16 - - 
4.  
Croscarmellose 
Sodium 
- 12 - - 16 - 
5.  
Sodium Starch 
Glycollate 
- - 12 - - 16 
6.  Aspartame 2  2 2 2  2 2 
7.  
Colloidal Silicon 
Dioxide 
1.5 1.5 1.5 1.5 1.5 1.5 
8.  
Magnesium 
Stearate 
1.5 1.5 1.5 1.5 1.5 1.5 
 Net Total 200.00 200.00 200.00 200.00 200.00 200.00 
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 Direct Compression Method 
 Weigh the ingredients Dexibuprofen, Diluents (Microcrystalline cellulose PH 102) and 
superdisintegrant (Sodium Starch Glycollate, Croscarmellose Sodium, Crospovidone) and 
sift individually through 40# sieve and Colloidal Silicon Dioxide, Sweetener, Lubricant 
through 60# sieve. 
 Mix all the ingredient in poly bags for 5 min. 
 Above blend passed through 40 # mesh and mix it. 
 Lubricated blend was compressed into tablets using 6.35mm Flat Face Round 
edged punch set using a eight station tablet press. 
 Compression was carried out using “D” tooling punches sets. 
4.6 EVALUATION 
Prepared Orodispersible tablets were evaluated for the following parameters.  
a. Physical characterization 
 Physical appearance 
 Hardness, Thickness. 
 Disintegration time 
 Friability. 
 Water absorption ratio 
 Wetting time 
 Weight variation. 
 Dissolution (In-Vitro release) 
b. Stability study of optimized formulation as per ICH 
 
A)  Physical Characterization67 
 Physical appearance:67 
The general appearance and elegance of tablet was identified visually, which include 
tablet size, shape, color, presence or absence of an odor, taste, surface texture and 
avoid of sticking etc. 
 
 Hardness:67 
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Tablets require certain amount of strength or hardness, to withstand mechanical shocks of 
handling in manufacture, packaging, and shipping.    The most widely used apparatus to 
measure tablet hardness (crushing strength) is the Schleuniger hardness tester.  
Method: Ten tablets were randomly selected and hardness was measured in Schleuniger 
hardness tester. The average was taken as hardness of the tablet. 
 In vitro disintegration test:67 
In vitro disintegration time was measured using USP disintegration test apparatus. Randomly 
six tablets were selected from each batch for disintegration test. Disintegration test was 
performed in 900ml distilled water at 37±0.5 °C temperature and at the rate of 30±2 
cycles/min. 
 Thickness: 67 
Ten Tablets were selected randomly from individual formulations and thickness was 
measured by using vernier caliper scale, which permits accurate measurement. 
 Friability:67 
Friability is related to the ability of tablet to withstand both shocks and abrasion without 
crumbling during manufacturing, packing, transportation and consumer handling. Friability 
can be evaluated by means of friability test apparatus (The Roche friabilator). Compressed 
tablets that loose less than 0.5% to 1.0% in weight are generally considered acceptable. 
Method: Ten tablets were weighed (initial wt.) and then transfer into Rocha friabilator. It was 
subjected to 100 revolutions in 4 minutes. The tablets were dedusted and reweighed (final 
wt). These two weights were applied to following formula and friability was calculated. 
       (Initial Weight – final weight) 
                      % Friability      =    ---------------------------------------    x 100 
       (Initial weight)  
 
 Water absorption ratio:68    
              A piece of tissue paper  folded  twice  was  placed in a  small petridish  containing 6 
ml  of   distilled water.  A tablet  was put on the paper  and time  required for  complete 
wetting  was  measured.  The wetted tablet was then weighed.  Water  absorption ratio, R, was 
determined using equation: 
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         ( Wa - Wb )   
                                          R     =    ---------------------   x 10 
      Wb   
                  Where,  Wb = weight  of  the  tablet before water  absorption 
                                 Wa = weight of   the  tablet after  water absorption  
 Wetting time:67 
For measurement of wetting time five circular tissue papers of 10 cm diameter are placed in a 
petri dish with a 10 cm diameter. 10ml of water-containing Eosin, a water-soluble dye, is 
added to petri dish. A tablet is carefully placed on the surface of the tissue paper. The time 
required for water to reach upper surface of the tablet is noted as a wetting time. 
 Weight variation:67 
Twenty tablets were taken randomly, weigh individually and average weight was determined. 
The individual tablet weight was compared with average tablet weight. 
 
Table 9 : Weight variation of tablets as per USP 
Avg. Weight(mg) Maximum % difference allowed 
≤ 130  ± 10 
130-324 ± 7.5 
≥ 324 ± 5 
 
 In vitro dissolution study69 
Medium          : 900 ml; Phosphate buffer pH 6.8 
Apparatus       : USP-II (paddle) 
RPM            : 50 
Temperature   : 37C  0.5C 
Time  : 60 minutes 
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Preparation of dissolution medium  (Phosphate buffer pH6.8) : 
Take  0.94g  of  NaOH  and 6.845g  of  KH2PO4  in 1000ml volumetric flask,  and made upto 
the volume with distilled water to 1000 ml.   
Test solution: Set the dissolution parameters of the instrument as mentioned above. 
Place one tablet each in six different baskets and operate the apparatus exactly for 
specified time. At the end of specified time, withdraw about 10 ml of solution from a 
zone midway between the surface of the dissolution medium and top of the basket, 
not less than 1 cm from the bowl wall. Filter the solution through 0.45 m Millipore 
HVLP filter; collect the filtrate by discarding first few ml of the filtrate. 
Procedure: Measure the absorbance of test sample solution in 1 cm cell or cuvette on 
UV spectrophotometer (1700 Shimadzu) at 221 nm, using dissolution medium 
(phosphate buffer pH 6.8) as blank. Then Calculate the quantity as percentage of Drug 
dissolved or released. 
B)  Stability Study of Optimized Formulation 70,71 
Stability testing of drug products begins as a part of drug discovery and ends with the demise 
of the compound or commercial product. FDA and ICH specifies the guidelines for stability 
testing of new drug products, as a technical requirement for the registration of 
pharmaceuticals for human use. 
The ICH Guidelines have established that long term stability testing should be done at 
250C/60% RH; stress testing should be done at 400C/75%RH for 6 months. If significant 
change occurs at these stress condition, then the formulation should be tested at an 
intermediate condition i.e. 300C/65%RH.  
                                      Table 10 : ICH guide lines for stability study 
Study Storage condition Time period 
Long term* 
25°c±2°C/60% RH±5%RH 
or 
30°c±2°C/65%RH±5% RH 
12 month 
Intermediate** 30°c±2°c/65% RH±5% RH 6 month 
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In the present work stability study was carried out for the optimized formulation for 
following condition and time period, 
 40° C / 75% RH for 1 month 
Then tablets were evaluated for hardness, drug content, and dissolution study and compared 
with tablets which were evaluated immediately after manufacturing.
Accelerated 40°c±2°c/75% RH±5% RH 6 month 
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5. RESULTS AND DISCUSSION 
 
5.1 PRE-FORMULATION STUDIES: 
 
 Organoleptic characteristics: 
Table 11 : Organoleptic properties of Dexibuprofen 
Properties Results 
Colour            White  
Taste Bitter  
Odour Odorless 
 
 Solubility:              
Table 12 : Results of solubility study 
Sr. No. Dissolution media 37°C Solubility(mg/L) 
1.  Purified Water 21 
2.  0.1N Hydrochloric Acid 15 
3.  Acetate Buffer pH 4.5 17 
4.  Phosphate Buffer pH 6.8 20 
5.  Phosphate Buffer pH 7.4 18 
 From above data stated that drug is sparingly water soluble. 
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 Particle size distribution:    
  By Malvern master seizer, dry method 
 
Table 13 : Dexibuprofen Particle size 
Particle size Results 
10 % Particles < 4  
40 % particles < 10  
90 % Particles < 21  
 
 
 Physico-mechanical characterization: 
Table 14 : Dexibuprofen Physico-mechanical properties 
Sr. No. Parameters Results Inference 
1.  Bulk Density 0.43 gm/ml - 
2.  Tapped Density 0.55 gm/ml - 
3.  Carr’s index 21.81 % Passable 
4.  Hausner Ratio 1.27 Passable 
5.  Angle of Repose 39.45 Good 
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Table 15 : Physico- mechanical properties of Formulations 
Batch 
Bulk 
Density(g/ml) 
Tapped 
Density(g/ml) 
Carr's 
Index 
Hausner's 
ratio 
Angle of 
Repose(θ) 
F1 0.414 0.542 23.616 1.309 40
o27’ 
F2 0.420 0.543 22.65 1.292 39
o14’ 
F3 0.440 0.535 17.757 1.215 38
o21’ 
F4 0.455 0.540 15.74 1.186 35
o14’ 
F5 0.460 0.541 14.97 1.170 33
o17’ 
F6 0.462 0.542 14.760 1.173 32
o12’ 
F7 0.462 0.541 14.602 1.170 33
o15’ 
F8 0.463 0.543 14.732 1.172 32
o10’ 
F9 0.463 0.542 14.57 1.170 32
o09’ 
F10 0.461 0.541 14.78 1.173 32
o12’ 
F11 0.462 0.540 14.44 1.168 31
o25’ 
F12 0.465 0.540 13.88 1.161 31
o10’ 
 
 Moisture content: 
Moisture content was determined by halogen moisture analyzer.  Drug has 
moisture content of 0.3 % w/w. which is within limit. 
 Drug potency calculation: 
                                         Assay × (100 – Moisture) 
     100                                           
 
Assay on as is basis = 
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      =     98.5 × (100 – 0.3)  
                     100 
               =   98.20 % 
 
                                               Assay × 100                         98.5 × 100 
        Assay on as is basis                   98.20      
 
Assay on 100% basis = 100.3  
 
 
 Flow properties of the Dexibuprofen blend, resistance to particle movement can be 
judged from the bulk density, tapped density, compressibility index, Hausner’s ratio. This 
measurement gives qualitative and quantitative assessment of internal cohesive and frictional 
force under low levels of external loading as might be applied in mixing and tabletting. The 
bulk density was found within the range of 0.414 to 0.465 g/cc . The tapped density was 
found within the range of 0.535 to 0.543 g/cc. Using the density data, Hausner’s ratio and 
Carr’s index was calculated. The Hausner’s ratio was found within the ranges of 1.16 to 1.3 
which indicates better flowability. The Carr’s index was found within the ranges of 13.88 to 
23.61 explaining good flow properties. 
 
 
 
 
 
 
 
 
 
 
 
Assay on 100% basis   = = 
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Drug-Excipient Compatibility Study: 
1) Physical observation: 
 
Table 16 : Results for drug-excipient compatibility 
Name of Sample Ratio 
Observation 
Initial RT initial 40
0/75%RH 
4weeks 
Dexibuprofen -- 
White powder, 
free flowing. No 
aggregates 
White powder, 
free flowing. 
No aggregates 
Whitepowder, 
free flowing. 
No aggregates 
Dexibuprofen + 
Microcrystalline 
cellulose 
1:5 Do No change No change 
Dexibuprofen + 
Crospovidone 1:5 Do No change No change 
Dexibuprofen + 
Croscarmellose 
Sodium 
1:5 Do No change No change 
Dexibuprofen + 
Sodium Starch 
Glycollate 
1:5 Do No change No change 
Dexibuprofen + 
Colloidal Silicon 
Dioxide
 
1:5 Do No change No change 
Dexibuprofen + Mg. 
Stearate 1:5 Do No change No change 
Dexibuprofen + 
Aspartame 1:5 Do No change No change 
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Compatibility test – FT-IR method: 
Dexibuprofen and excipients are subjected to FT-IR spectral analysis. The drug was 
Compatible with excipients since no significant changes were observed in intensity and 
position of the peaks in the spectra. The results are shown in graph. 
Figure 9 :   FT-IR spectra of pure drug of Dexibuprofen 
      
 
     Figure 10 :  FT-IR spectra of optimized formulation of Dexibuprofen ODT 
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These are the compatibility studies showed that there was no chemical change or interaction 
between drug and selected excipient. Based on physical and chemical compatibility results. 
The above excipients selected are suitable  for formulation development of Dexibuprofen. 
5.2 EVALUATION OF ORODISPERSIBLE TABLETS: 
Physical Characterization: 
Physical appearance: 
The physical examination of tablets showed that the tablets were round and circular shape. 
The studies also indicated that there were no cracks on the tablets. The data indicates that all 
the formulations were good. 
Post compression Parameters: 
 Tablets  were compressed  at average wt. of 200±5.0 mg  with  thickness  of  
   2.24±0.2 mm. 
                     Table 17 : Post compression Parameters of batch F1 to F12 
Batch 
Hardness 
(kg) 
Disintegrating 
time (sec) 
Wetting 
time 
(sec) 
Water 
absorption 
ratio 
Friability 
(%) 
Average 
Weight 
 
F1 2.0-3.0 56 42 19.45 0.49 199 
F2 2.0-3.0 45 33 24.89 1.36 199 
F3 2.5-3.5 27 45 23.09 0.19 200 
F4 2.5-3.5 36 43 25.56 0.16 199 
F5 2.5-3.5 25 54 20.19 0.14 196 
F6 2.5-3.5 21 55 23.34 0.18 196 
F7 2.5-3.5 30 45 24.35 0.15 200 
F8 2.5-3.5 20 41 24.45 1.68 200 
F9 2.5-3.5 16 46 25.14 0.21 201 
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F10 2.5-3.5 25 39 24.98 0.17 200 
F11 2.5-3.5 18 44 25.43 0.35 199 
F12 2.5-3.5 15 36 27.08 0.27 202 
 
In vitro dissolution study: 
Table 18 : Dissolution study of Formulation Batch F1 to F6. 
 
Time 
(min) 
% Drug Release in 900ml 
 pH 6.8 Phosphate buffer  50 RPM, 37°C ± 0.1°C,   
USP Type II (Paddle) 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
2 1.91 0.94 4.31 4.04 6.41 14.82 
4 3.02 4.47 17.26 8.59 12.27 51.35 
6 4.62 5.42 34.96 12.98 29.31 69.19 
8 6.31 5.44 44.79 17.99 32.59 81.57 
10 7.95 7.06 54.08 32.59 38.96 88.13 
15 10.90 9.81 66.64 39.14 49.89 98.32 
20 14.54 11.58 79.21 47.70 56.08 101.78 
25 16.42 13 86.49 56.26 57.72  
30 24.94 14.62 91.95 62.82 63.91  
40 28.95 30.59 96.32 72.83 74.65  
45 33.68 33.32 96.69 77.38 79.18  
60 38.60 40.24 100.87 90.86 101.97  
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Figure 11 : Dissolution profiles of Dexibuprofen ODTs of batch (F1 – F3) 
 
 
 
 
Figure 12 : First–order release profiles of Dexibuprofen ODTs of batch (F1 – F3) 
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Figure 13 : Dissolution profiles of Dexibuprofen ODTs of batch  (F4 – F6) 
 
 
 
 
Figure 14: First–order release profiles of Dexibuprofen ODTs of batch  (F4 – F6) 
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Table 19 : Dissolution study of Formulation Batch F7 to F12 
Time 
(min) 
% Drug Release in 900ml 
pH 6.8 Phosphate buffer  50 RPM, 37°C ± 0.1°C,   
USP Type II (Paddle) 
F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
2 1.14 33.32 29.13 3.71 38.6 69.92 
4 2.74 58.26 62.27 10.48 66.2 90.68 
6 7.33 85.03 81.75 27.13 87.58 98.86 
8 12.47 91.77 90.68 30.22 96.69 102.88 
10 16.09 94.14 97.05 39.15 102.88  
15 35.14 97.78 102.18 51.89   
20 48.07 98.14  61.54   
25 54.08 98.44  72.1   
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30 65.53 98.86  76.66   
40 81.21 102.05  90.13   
45 93.95   92.86   
60 93.95   94.5   
    
 
 
 
 
 
 
 
 
 
Figure 15 : Dissolution profiles of Dexibuprofen ODTs of batch  (F7 – F9) 
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Figure 16: First–order release profiles of Dexibuprofen ODTs of batch  (F7 – F9) 
 
       
 
 
 
 
 
Figure 17 : Dissolution profiles of Dexibuprofen ODTs of batch(F10–F12)  
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Figure 18: First–order release profiles of Dexibuprofen ODTs of batch(F10–F12) 
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according to the procedure specified in the I.P. The results of the tests were tabulated and 
found to be within the Pharmacopoeial limits. This study indicated that all the prepared 
formulations were good. 
The disintegration times of  Dexibuprofen ODTs containing Sodium starch glycollate as 
superdisintegrant  were low when compared to those of other formulations. The increasing 
order of effectiveness of superdisintegrants with respective to the disintegration time in 
Dexibuprofen ODT's was found to be  
 Sodium starch glycollate > croscarmellose sodium > crospovidone 
Again in formulations containing Sodium starch glycollate i.e. F3, F6, F9, F12, formulation 
F12 of 8% concentration of superdisintegrant show low disintegration time. 
Finally, the dissolution test showed that the dissolution rates of Dexibuprofen ODT's 
containing sodium starch glycollate as superdisintegrant were high than other formulations, 
Among the formulations containing Sodium starch glycollate, i.e. F3, F6, F9, F12, 
formulation F12 of 8% concentration of superdisintegrant shows high dissolution rate. So, by 
considering all results of pre-compression and post-compression parameters  formulation F12 
is considered as optimized formulation. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                   Results and Discussion                          
         
                                                                                                                                         Page 83                           
5.3 STABILITY STUDIES OF OPTIMIZED FORMULATION 
 
Table 20 : Comparison profile of stability batch, initial and 1 month 
Parameter 
           Condition 40° C / 75% RH  
Initial 1 months 
Hardness 2.5-3.5 2.5-3.5 
Friability 0.27 0.29 
Disintegration time 15 16 
Wetting time 36 42 
                 
 
 
Table 21 : Dissolution profile of stability batch, initial and 1 month. 
Time   
(min) 
% drug release 
Initial 1 months 
0 0 0 
2 69.92 70.2 
4 90.68 90.1 
6 98.86 99.4 
8 102.2 100.6 
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Figure 19 : Dissolution profile of Stability batch of initial and 1 months for 
optimized formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22 : Drug release kinetics of Dexibuprofen ODT Formulations F1 - F12 
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FORMULA 
           Zero order First order 
K0 r2 K1 r2 
F1 0.689 0.983 0.007 0.992 
F2 0.656 0.907 0.007 0.944 
F3 2.326 0.534 0.076 0.98 
F4 1.753 0.895 0.035 0.971 
F5 1.904 0.782 0.030 0.973 
F6 6.739 0.635 0.348 0.895 
F7 1.857 0.952 0.051 0.959 
F8 3.885 0.620 0.15 0.864 
F9 9.048 0.654 0.348 0.974 
F10 2.073 0.766 0.051 0.989 
F11 12.13 0.863 0.419 0.957 
F12 14.99 0.866 0.730 0.978 
 
From the results of in-vitro drug release profile it was evident that kinetics of drug 
release was 1st  order for all prepared ODT's as the plot between log% drug remained  
Vs time showed good linearity. The coefficient of  regression (r2) values closer to1.
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6. CONCLUSION 
           The present work was aimed to develop a stable, safe and convenient           oro-
dispersible tablets of Dexibuprofen for rapid therapeutic action and to avoid first pass 
metabolism. 
            Dexibuprofen is a BCS class II drug, So rapid disintegration of the tablet was desired 
for achieving quick onset of action. For this purpose, suitable super disintegrants were added 
and tablets were disintegrated within seconds.  
           Twelve formulations of fast dissolving tablets of Dexibuprofen were successfully 
prepared using sodium starch glycollate, croscarmellose and crospovidone by direct 
compression method. We have manufactured ODTs with quality and product consistent by a 
production friendly direct compression technique which avoids costly technology, equipment 
and lengthy manufacturing process. 
The tablets were evaluated for parameters like thickness, hardness, friability, in- vitro 
disintegration time, wetting time, water absorption ratio, and in- vitro drug release studies. 
 Based on the results, formulation containing 8% Sodium starch glycollate (F12) was 
identified as ideal and better formulation among all formulations developed for Dexibuprofen  
tablets. 
 In vitro release of optimized formulation of Dexibuprofen fast dissolving tablets of 
F12 was found to be 98.86% drug release within 6 min. 
The optimized formulation was subject to stability studies for 1 month by  storing 
them at 40C/75%RH. Results of physical appearance, hardness, friability, disintegration test, 
and % drug release have shown that there was no significant change at storage condition. 
They were within the limits as per stability protocol given in  ICH guide lines in formulations.   
         Thus,  Dexibuprofen oro-dispersible tablets were successfully developed. 
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7. SUMMARY 
  Dexibuprofen is an non-steroidal anti-inflammatory drug (NSAID) , a propionic acid 
derivative with analgesic and antipyretic properties. Dexibuprofen inhibits cyclooxygenases 
and activates peroxisome proliferators-activated receptors; both of these actions result in 
reduced inflammation. 
  Dexibuprofen is an NSAID that is advocated for the treatment  to relieve pain 
and inflammation associated with osteoarthritis, dysmenorrhea. Apart from pain it is 
also used in treatment of pain associated with toothache  and other painful  problems 
of the muscles and bones. Dexibuprofen is rapidly eliminated from the body due to 
hepatic metabolism. Thus by formulating it as ODT its degradation by liver can be 
bypassed and thus, its bioavailability can be increased 
The present study is an attempt to develop and formulate fast dissolving tablets of 
Dexibuprofen with superdisintegrants which disintegrates in matter of seconds in the oral 
cavity, thereby reducing the time of onset of pharmacological action and to prevent the first 
pass metabolism of Dexibuprofen.   
 In this system direct compression  was used, Microcrystalline cellulose (MCC)  is 
used as a diluent, sodium starch glycollate (SSG), croscarmellose sodium and 
crospovidone(CP) were used as superdisintegrants, aerosil are used as flow promoter, 
magnesium stearate was used as lubricant, aspartame as sweetener. 
The drug- polymer compatibility was confirmed by FTIR studies. The results 
obtained by FTIR studies revealed that there was no chemical interaction between the pure 
drug and excipients. Direct compression method was employed to formulate the tablets, 
because of its cost effectiveness and due to reduced number of manufacturing steps. 
The pre-compression parameters like bulk density, tapped density, Carr’s ‘index and 
angle of repose were determined. The final formulation showed acceptable flow properties. 
The post-compression parameters like the thickness, hardness, friability and in vitro 
disintegration time, wetting time, water absorption ratio and in vitro drug release were carried 
out and the values were found to be within IP limits. 
The final optimized formulation of Dexibuprofen tablets containing 8% Sodium 
starch glycollate (F12) revealed that formulated rapid dissolving tablets of Dexibuprofen were 
effective and better to meet patient compliance. 
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